Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials

IMPORTANCE: Alzheimer disease (AD), a neurodegenerative disease characterized by β-amyloid plaques and τ tangles in the brain, represents an unmet medical need with no fully approved therapeutics to modify disease progression. OBJECTIVE: To investigate the safety and efficacy of crenezumab, a humani...

Descripción completa

Detalles Bibliográficos
Autores principales: Ostrowitzki, Susanne, Bittner, Tobias, Sink, Kaycee M., Mackey, Howard, Rabe, Christina, Honig, Lawrence S., Cassetta, Emanuele, Woodward, Michael, Boada, Mercè, van Dyck, Christopher H., Grimmer, Timo, Selkoe, Dennis J., Schneider, Andres, Blondeau, Kathleen, Hu, Nan, Quartino, Angelica, Clayton, David, Dolton, Michael, Dang, Yifan, Ostaszewski, Beth, Sanabria-Bohórquez, Sandra M., Rabbia, Michael, Toth, Balazs, Eichenlaub, Udo, Smith, Jillian, Honigberg, Lee A., Doody, Rachelle S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486635/
https://www.ncbi.nlm.nih.gov/pubmed/36121669
http://dx.doi.org/10.1001/jamaneurol.2022.2909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486635/
https://www.ncbi.nlm.nih.gov/pubmed/36121669
http://dx.doi.org/10.1001/jamaneurol.2022.2909

Ejemplares similares